First European approval for new Decapeptyl indication

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) – in coordination with 14 other European regulatory agencies – has approved a new Decapeptyl (triptorelin pamoate) indication for pre-menopausal women with early-stage breast cancer.

This decision approves the use of the product from French pharma Ipsen (Euronext: IPN) as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.

Alexandre Lebeaut, chief scientific officer at Ipsen, said: “We are pleased to receive the first European approval which brings a new treatment option offering disease-free survival benefit for high-risk pre-menopausal breast cancer patients.